Prostate Cancer

Cancer is commonly defined as the uncontrolled division of abnormal cells. When cells become aged or damaged, they are replaced with new cells. Sometimes the genetic material (DNA) of a cell can become damaged or altered, producing mutations that negatively affect cell growth and division. Prostate cancer may be slow growing, or it may be aggressive. When confined within the prostate or another organ, cancer is known to be “localized” or “organ-confined”. When cancer cells spread throughout the body (metastasize) via blood and lymph systems, they can become life threatening.

Prostate cancer is one of the leading forms of cancer diagnosed in North American men, typically in men over the age of 50. In its early stages, prostate cancer has no symptoms, which is why it’s important for men to have regular medical checkups. If diagnosed early, prostate cancer is often curable. Treatment can eliminate symptoms and prolong life expectancy.

Prostate_Cancer_pic

Risk Factors

There are several risk factors for prostate cancer, some modifiable, others not. These include:

  • Age – Prostate cancer is most commonly diagnosed in men over the age of 50.
  • Family History – Research shows an increased risk for prostate cancer in sons, brothers and fathers of men with the disease.
  • Genetics – Inherited gene changes may increase prostate cancer risk.
  • Diet – High fat, high calcium and high red meat diets may increase the risk of developing prostate cancer.
  • Ethnicity – Studies have shown that prostate cancer is more common in men of African ethnicity.

For more information about the prostate, visit the Prostate Cancer Canada website.

2018 APCaRI Fall Symposium

Our fall APCaRI 2018 symposium wrapped up on Saturday afternoon after two days of excellent seminars, great food, lots of coffee, bowling, hikes around Banff, get-togethers at the local pub, and beautiful fall weather with minimal snowfall!

The APCaRI meeting was attended by people from across Canada and the USA representing the Alberta Cancer Foundation, Bird Dogs for Prostate Cancer Research, Cross Cancer Institute, DynaLIFE Medical Labs, Edmonton Health City, Entos Pharmaceuticals, Institute of Health Economics, Nanostics Inc, Northern Alberta Urology Centre, Oisin Biotechnologies, PandiaDX, PROSTAID Calgary, Prostate Cancer Centre, Prostate Cancer Support Group, University of Alberta, University of Calgary, Western University, and the Yukon Hospital Corporation.
The invited speakers gave excellent keynote talks that kick-started interesting conversations during the meeting.

Dr. Alison Allan from Western University gave the Friday keynote seminar on developing circulating tumour cells as liquid biospies for early detection of cancers.

Dr. Melina Cimler, CEO of PandiaDX, and Saturday’s keynote speaker, outlined the potentially complex regulatory pathways that molecular diagnostic companies need to navigate when pursuing regulation in the USA.


Thank you to Rume Djebah for organizing the 2018 APCaRI Fall Symposium!

- Perrin Beatty